01 Shift towards Affordable and Effective Digital Health Solutions The market for therapeutics apps is witnessing a notable shift toward affordable and effective digital health solutions, mainly driven by the need to address rising healthcare costs and limited access to traditional in-person care. Digital therapeutics offer scalable, evidence-based interventions for a range of conditions, including chronic diseases, mental health challenges, and substance use disorders, providing accessible alternatives to conventional treatments.
02 For instance, In May 2022, the UK's National Institute for Health and Care Excellence (NICE) recommended Sleepio, a digital CBT-based app, as an effective alternative to sleeping pills for insomnia. This endorsement highlights the app's potential to reduce reliance on medication and address therapist shortages. Likewise, a recent study by UT Health San Antonio demonstrated that the WEconnect Health app, combined with medication, reduced opioid use by 35% and increased treatment duration by 19%. The app's contingency management features, including financial incentives, contributed to these outcomes. These examples underscore the growing role of therapeutic apps in modern, value-driven healthcare.
June 2026 Shionogi & Co., Ltd. launched ENDEAVORRIDE, Japan's first digital therapeutic app approved as an adjunctive treatment for pediatric ADHD, expanding the adoption of prescription digital therapeutics in Asia.
May 2026 DarioHealth expanded its AI-powered digital therapeutics platform with enhanced GLP-1 companion features, integrating personalized coaching, medication adherence support, and remote monitoring for obesity and cardiometabolic disease management.
February 2026 Samsung partnered with PharmEasy and Tata 1mg to introduce the Find Care feature within the Samsung Health app, enabling medicine ordering, diagnostic test booking, and online consultations through a single digital health platform.
October 2025 Otsuka Pharmaceutical and Click Therapeutics expanded their collaboration to accelerate the development and commercialization of prescription digital therapeutics targeting major depressive disorder and other neuropsychiatric conditions.